key: cord-0252393-1ssdromv
authors: Najafi, Ali; Ghanei, Mostafa; Janbabaei, Ghasem; Velayati, Ali Akbar; Saadat, Seyed Hassan; Jamaati, Hamidreza; Tabarsi, Payam; Dastan, Farzaneh; Ram, Malihe; Darabi, Enayat; Fathi, Saeid; Gholami Fesharaki, Mohammad; Ghazale, Amir Hosein; Saloo, Shahrzad
title: Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View
date: 2020-11-03
journal: Tanaffos
DOI: nan
sha: bc474dd88144ce2e370b45a971b3a88540309b4e
doc_id: 252393
cord_uid: 1ssdromv

BACKGROUND: The Coronavirus disease 2019 (COVID-19) outbreak quickly has spread and became a pandemic. However, no approved therapeutics or effective treatment is available for the treatment of these patients. The present study was done to retrospectively assess the treatment strategies (e.g., pharmaceutical care services) for COVID-19 patients in selected hospitals and highlight the importance of such services in the management of a pandemic. MATERIALS AND METHODS: Data from a series of COVID-19 patients (978 patients; 658 males [66.9%] and 324 females [33.1%]) admitted to the selected hospitals in Tehran from 20 February to 19 March 2020 were retrieved retrospectively from the Health Information System (HIS) of the hospitals. The statistical tests were used for analyzing the effect and correlation of the variables (drugs) with the average length of stay (ALOS) in the hospital. RESULTS: Diverse medication classes and old drugs with or without strong evidence of therapeutic effects against the novel coronavirus, some previously tried as a treatment for SARS-CoV and MERS-CoV, were mostly used for the treatment of patients in the hospitals. Many medications (broad-spectrum antibiotics and antivirals) or combination therapies are used without evidence of their therapeutic effects during pandemics. CONCLUSION: Therefore, guidelines should be provided for the off-label use of these drugs by policymakers and stakeholders during a pandemic emergency due to high demands. Also, monitoring of the HIS data can play an important role in improving public health response to emerging diseases.

The present study was conducted to retrospectively assess the treatment strategies (e.g., pharmaceutical care services) for COVID-19 patients in selected hospitals and to highlight the importance of pharmaceutical care services in the management of a pandemic. This study also highlights the role of Hospital Information System (HIS) in improving public health response to emerging diseases.

Data from a series of COVID- 19 Figure 2A shows the downward trend in the ALOS over a month. The mean ALOS for patients over 40 years of age was one day longer than the patients under 40 years of age (6.13±3.79 and 6.89±3.87, respectively; P=0.003).

With increased experience in the management of the disease, the medical team was able to better characterize the COVID-19 patients and make a timely diagnosis of the disease, and the therapeutic strategies also improved one The correlations between the ALOS and antibiotic, antiviral, and corticosteroid therapies are presented in Tables 3-5 . As shown in Table 2 , except for azithromycin and ceftriaxone, other antibiotic medications did not show a significant correlation with the ALOS, in other words, no positive clinical significance was observed by correlation analysis. outbreak, hospitals are facing problems in terms of drug supply and pharmaceutical care and personnel.

A study conducted in Wuhan reported that 15% of pandemic.

Antiviral and antimalarial drugs were widely recommended by the latest Iranian MOHME guidelines and doctors' opinions ( Figure 2 B and C) . In the studied hospital, the percentages of patients who received the antiviral and anti-malaria medications were as follows:

oseltamivir (Tamiflu; 92%), lopinavir/ritonavir (84%), ribavirin (26%), and hydroxychloroquine (69%) ( Table 1 ). antiviral drugs during the first few weeks of the outbreak followed by a steady increase with a very gentle slope, indicating a reduction in the use of broad-spectrum antivirals over time ( Figure 2B ). It is noteworthy that drug stockpile, safety, and cost should be considered when prescribing antiviral drugs. where its correlation analysis was not possible.

One of the main limitations in this study was the lack of accessibility of the duration of antibiotic, antiviral, and antimalarial drug therapies, as well as the patients'

outcomes (e.g., mortality, laboratory findings, etc.) due to lack of data or missing data in the HIS of the hospital. 

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with (COVID-19)

Antibiotics, pregnancy, and fetal mental illnesses: where is the link?

Sepsis and septic shock

Lopinavir-ritonavir in severe COVID-19

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Compounds with Therapeutic Potential against Novel Respiratory

New insights into the antiviral effects of chloroquine

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral Najafi A

infections in the 21st century

Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin

Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

On the use of corticosteroids for 2019-nCoV pneumonia

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Current status of potential therapeutic candidates for the COVID-19 crisis

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19